Services will include the demonstration of protein expression for therapeutic antibody cross-reactivity (TCR), cell signalling pathway intermediates/surrogates, biomarker efficacy/proof of principle/ proof of mechanism studies, pre and post therapy patient biopsy screening, pharmacology studies, bio-similar studies, companion diagnostic studies, IHC assay development of novel antibodies, aptamer staining.  We use tissue samples as frozen or FFPE wax blocks and we can provide IHC assay development or transfer-in client’s methods which we will validate and optimise to demonstrate they are fit for purpose.

Histologix uses Ventana Discovery and Benchmark, XT and Ultra automated IHC staining platforms and also multiple LabVision systems.

Histologix can provide multi-staining assays in order to demonstrate two or more targets in the same section.  Chromogenic methods are limited to two target while fluorescent method may identify up to four targets.

Related services


Using a range of cutting edge technologies, Histologix is able to produce a high end quality service for clinical trials.

Find out more

News & resources